Enovis (ENOV) Equity Income (2022)

Enovis (ENOV) reported Equity Income of $30.3 million for Q4 2022, up 148.0% quarter-over-quarter from -$63.1 million in Q3 2022.

Enovis (ENOV) Equity Income (2022) Analysis & Trends

Enovis (ENOV) has 1 years of Equity Income data on file, last reported at $30.3 million in Q4 2022.

Equity Income for Q4 2022 came in at $30.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $30.3 million (down 70.5% YoY), and the FY2022 annual result was $102.7 million, changed N/A from the prior year.
Equity Income advanced to $30.3 million in Q4 2022 per ENOV's latest filing, from -$63.1 million in the prior quarter.
Over five years, Equity Income peaked at $135.5 million in Q3 2022 and troughed at -$63.1 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	-
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	-
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	-
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	-
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	-
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	4.68 Mn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	-
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	-
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	-
10	Enovis	1.26 Bn	1.23 Bn	365.49 Mn	-

Download Data